Note that because CSF Aβ42 decreases and brain tau-pathology increases in AD subjects, we selected CpGs or DMRs with opposite directions in blood DNAm-to-CSF Aβ42 and blood DNAm-to-Braak stage associations. This evidence concerns the gene MAPT and Alzheimer disease.